Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/8/2025

Management of Persistent Lower Urinary Tract Symptoms in Elderly Men

Patient Assessment and Current Status

  • The patient has bothersome urinary frequency, urgency, and nocturia despite 6 weeks of tamsulosin therapy, with a significantly enlarged prostate of 60g, which is twice the normal size, and a mildly elevated post-void residual of 100ml 3
  • The patient's prostate is significantly enlarged at 60g, which is more than twice the normal size of less than 30g, and urinalysis is unremarkable, ruling out infection as a cause 1
  • The patient has hypertension, with a blood pressure of 145/96, which should be considered in management 2

Rationale for Treatment

  • The American Urological Association recommends 5-alpha reductase inhibitors (5-ARIs) for men with lower urinary tract symptoms (LUTS) and prostatic enlargement greater than 30cc, making this patient an ideal candidate 1
  • Combination therapy with an alpha-blocker and 5-ARI is appropriate and effective for patients with LUTS associated with demonstrable prostatic enlargement, and 5-ARIs reduce prostate size and prevent disease progression, reducing the risk of acute urinary retention and need for surgery 2
  • Alpha blockers like tamsulosin provide rapid symptom relief but do not address the underlying prostatic enlargement, whereas 5-ARIs have been shown to reduce the risk of disease progression 2

Treatment and Follow-up

  • The patient should be started on a 5-ARI, such as finasteride or dutasteride, in addition to continuing tamsulosin, and scheduled for follow-up in 3 months to assess the efficacy of combination therapy, as 5-ARIs require at least 3 months to show clinical effect 1, 2
  • Blood pressure should be monitored, and separate treatment for hypertension considered if needed, as the patient has a history of hypertension 2

Expected Outcomes and Important Considerations

  • Combination therapy is expected to improve symptom control, reduce prostate volume over time, and decrease the risk of disease progression and complications 2
  • 5-ARIs reduce serum PSA by approximately 50%, which should be considered in future prostate cancer screening, and common side effects include sexual adverse events, such as decreased ejaculation, decreased libido, and erectile dysfunction 2
  • If combination therapy fails after 3-6 months, urologic referral for additional workup and consideration of surgical options would be warranted, and patients with significant nocturia may benefit from additional assessment with a frequency-volume chart 1, 4

Alternative Treatment Options

  • Anticholinergics could worsen voiding symptoms in a patient with enlarged prostate and may increase post-void residual, and immediate surgical intervention is not indicated as the patient has not failed an adequate trial of medical therapy 5, 1
  • Watchful waiting is inappropriate given the patient's bothersome symptoms despite current therapy, and the patient should be closely monitored and treated accordingly 1